Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis
1 other identifier
observational
80
1 country
1
Brief Summary
changes in high sensitive C reactive protien with different treatment modalities in acute pancreatitis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2018
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 11, 2018
CompletedStudy Start
First participant enrolled
November 9, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 9, 2018
CompletedFirst Posted
Study publicly available on registry
November 14, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
October 8, 2019
CompletedNovember 14, 2018
November 1, 2018
Same day
October 11, 2018
November 9, 2018
Conditions
Outcome Measures
Primary Outcomes (3)
High sesitive C reactive protien
Level of High sesitive C reactive protien expected to be changed with different lines of treatment and will be compaered
72hours
Serum Amylase
Level of Serum Amylase expected to be changed with different lines of treatment and will be compaered
72hours
Serum Lipase
Level of Serum Lipase expected to be changed with different lines of treatment and will be compaered
72hours
Study Arms (1)
Patients with acute pancreatitis
All patients will recive different lines of treatment {saline,antibiotics,dexamethasone}
Interventions
High sesitive C reactive protien will be evaluated at admission time and after 36 hours
Eligibility Criteria
Patients with acute pancreatitis
You may qualify if:
- Age\>=18 years
- Diagnosis of acute pancreatitis confirmed by at least 2 of the following:
- Typical epigastric abdominal pain
- Elevation amylase/lipase \>3 times upper limit normal and/or
- Confirmatory findings on cross-sectional imaging
- Enrollment within 8 hours of presentation
You may not qualify if:
- Class II or greater NYHA heart failure
- Oxygen dependent COPD
- Chronic kidney disease\>stage 2
- Existing necrosis on abdominal CT
- Organ dysfunction prior to enrollment
- Sepsis
- Acute respiratory distress syndrome
- Malignancy not in remission for at least 5 years
- Active drug use
- Known allergy to dexamethasone
- Altered mental status
- Insulin-requiring diabetes
- Abdominal surgery within 60days
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assiut University
Asyut, 171516, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
October 11, 2018
First Posted
November 14, 2018
Study Start
November 9, 2018
Primary Completion
November 9, 2018
Study Completion
October 8, 2019
Last Updated
November 14, 2018
Record last verified: 2018-11
Data Sharing
- IPD Sharing
- Will not share